Abliva AB is a Swedish pharmaceutical company specializing in the development of treatments for primary mitochondrial diseases. With a focus on environmental, sustainability, and governance practices, the company has a medium risk ESG score of 29.2. Abliva AB's portfolio includes projects at varying stages, with a particular emphasis on two main projects - KL1333 and NV354. KL1333 is a NAD+ and NADH regulator in late-stage development, while NV354 is an energy replacement therapy in preclinical development. Abliva AB has been granted orphan drug designation in Europe and the US for KL1333, showcasing its commitment to addressing rare and severe diseases. Located in Sweden, Abliva AB is at the forefront of pharmaceutical innovation in the region.